Eli Lilly, WuXi Biologics and Alexandria-backed cancer and orphan disease therapy developer Inhibrx has received $40m in funding from Viking Global Investors.

Inhibrx, a US-based biologic drug developer backed by corporate investors Eli Lilly and WuXi Biologics, raised $40m inĀ  convertible promissory note financing from hedge fund Viking Global Investors on Tuesday. Originally known as Tenium Therapeutics, Inhibrx has developed a protein engineering platform, SdAb, that is capable of generating treatments addressing complex diseases. The company is…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.